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STUDY QUESTION:What are the reported data on cycles in ART, IUI and fertility preservation (FP) interventions in 2016 as compared
to previous years, as well as the main trends over the years?
SUMMARY ANSWER: The 20th ESHRE report on ART and IUI shows a progressive increase in reported treatment cycle numbers in
Europe, with a decrease in the number of transfers with more than one embryo causing a reduction of multiple delivery rates (DR), as
well as higher pregnancy rates and DR after frozen embryo replacement (FER) compared to fresh IVF and ICSI cycles, while the outcomes
for IUI cycles remained stable.
WHAT IS KNOWN ALREADY: Since 1997, ART aggregated data generated by national registries, clinics or professional societies have
been collected, analysed by the European IVF-monitoring Consortium (EIM) and reported in 19 manuscripts published in Human
Reproduction and Human Reproduction Open.
STUDY DESIGN, SIZE, DURATION: Yearly collection of European medically assisted reproduction (MAR) data by EIM for ESHRE.
The data on treatments performed between 1 January and 31 December 2016 in 40 European countries were provided by either National
Registries or registries based on personal initiatives of medical associations and scientific organizations.
PARTICIPANTS/MATERIALS, SETTING, METHODS: In all, 1347 clinics offering ART services in 40 countries reported a total of
918 159 treatment cycles, involving 156 002 with IVF, 407 222 with ICSI, 248 407 with FER, 27 069 with preimplantation genetic testing,
73 927 with egg donation (ED), 654 with IVM of oocytes and 4878 cycles with frozen oocyte replacement (FOR). European data on IUI
using husband/partner’s semen (IUI-H) and donor semen (IUI-D) were reported from 1197 institutions offering IUI in 29 and 24 countries,
respectively. A total of 162 948 treatments with IUI-H and 50 467 treatments with IUI-D were included. A total of 13 689 FP interventions
from 11 countries including oocyte, ovarian tissue, semen and testicular tissue banking in pre-and postpubertal patients were reported.
MAIN RESULTS AND THE ROLE OF CHANCE: In 20 countries (18 in 2015) with a total population of approximately 325 million
inhabitants, in which all ART clinics reported to the registry, a total of 461 401 treatment cycles were performed, corresponding to a
mean of 1410 cycles per million inhabitants (range 82–3088 per million inhabitants). In the 40 reporting countries, after IVF the clinical
pregnancy rates (PR) per aspiration and per transfer in 2016 were similar to those observed in 2015 (28.0% and 34.8% vs 28.5% and
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34.6%, respectively). After ICSI, the corresponding rates were also similar to those achieved in 2015 (25% and 33.2% vs 26.2% and
33.2%). After FER with own embryos, the PR per thawing is still on the rise, from 29.2% in 2015 to 30.9% in 2016. After ED, the PR per
fresh embryo transfer was 49.4% (49.6% in 2015) and per FOR 43.6% (43.4% in 2015). In IVF and ICSI together, the trend towards the
transfer of fewer embryos continues with the transfer of 1, 2, 3 and 4 embryos in 41.5%, 51.9%, 6.2% and 0.4% of all treatments, re-
spectively (corresponding to 37.7%, 53.9%, 7.9% and 0.5% in 2015). This resulted in a proportion of singleton, twin and triplet DRs of
84.8%, 14.9% and 0.3%, respectively (compared to 83.1%, 16.5% and 0.4%, respectively in 2015). Treatments with FER in 2016 resulted in
twin and triplet DR of 11.9% and 0.2%, respectively (vs 12.3% and 0.3% in 2015). After IUI, the DRs remained similar at 8.9% after IUI-H
(7.8% in 2015) and at 12.4% after IUI-D (12.0% in 2015). Twin and triplet DRs after IUI-H were 8.8% and 0.3%, respectively (in 2015:
8.9% and 0.5%) and 7.7% and 0.4% after IUI-D (in 2015: 7.3% and 0.6%). The majority of FP interventions included the cryopreservation
of ejaculated sperm (n¼ 7877 from 11 countries) and of oocytes (n¼ 4907 from eight countries).
LIMITATIONS, REASONS FOR CAUTION: As the methods of data collection and levels of completeness of reported data vary
among European countries, the results should be interpreted with caution. A number of countries failed to provide adequate data about
the number of initiated cycles and deliveries.
WIDER IMPLICATIONS OF THE FINDINGS: The 20th ESHRE report on ART and IUI shows a continuous increase of reported
treatment numbers and MAR-derived livebirths in Europe. Being already the largest data collection on MAR in Europe, continuous efforts
to stimulate data collection and reporting strive for future quality control of the data, transparency and vigilance in the field of reproductive
medicine.
STUDY FUNDING/COMPETING INTEREST(S): The study has no external funding and all costs were covered by ESHRE. There are
no competing interests.
Key word: IVF / ICSI / IUI / egg donation / frozen embryo replacement / surveillance / vigilance / registry / data collection / fertility
preservation
Introduction
This is the 20th annual report of the European IVF-monitoring
Consortium (EIM) under the umbrella of ESHRE containing the data
on ART, IUI and fertility preservation (FP) as reported by 40 partici-
pating European countries in 2016 (Supplementary Data).
Eighteen previous reports published in Human Reproduction
(https://www.eshre.eu/Data-collection-and-research/Consortia/EIM/
Publications.aspx) and one in Human Reproduction Open (De Geyter
et al., 2020) covered treatment cycles from 1997 to 2015. As in previ-
ous reports, the printed version contains the five most relevant tables.
Twenty additional supplementary tables (Supplementary Tables SI–
SXX) are available online. The settings of the data are consistent with
those published in the previous reports, aiming at easier comparison
and assessment of trends. For the first time, an additional set of data
dealing with FP was collected and added to this report.
Material and methods
Data collected on an aggregate basis were provided by 40 European
countries, covering the following treatment modalities: IVF, ICSI, frozen
embryo replacement (FER), egg donation (ED), IVM, pooled data on
preimplantation genetic testing (PGT) and frozen oocyte replacement
(FOR). With regards to IUI, split data for use of husband’s/partner’s
semen (IUI-H) and donor semen (IUI-D) were included. The report
includes treatments started between 1 January and 31 December
2016. Data on pregnancies and deliveries were derived from follow-up
of treatments performed in 2016. In addition, data on FP, including
numbers and types of cryostored material and interventions for use of
stored material between 1 January and 31 December 2016, were
provided by 11 countries and reported as aggregated data of events
that occurred during a 1-year period.
The national representatives of 44 countries were asked to fill out
questionnaires, with other involved stakeholders when applicable. The
same data sets as in 2015 and additional data on FP for a total of 10
specific modules were sent using software designed for the specific
requirements of this data collection (Dynamic Solutions, Barcelona,
Spain). Besides evaluation of the plausibility of the results by the soft-
ware, other detected inconsistencies were clarified through contacts
between the administrator of the ESHRE central office (V.G.) and the
national representative.
The data were analysed and presented similarly to previous reports
(although with some additional subgroups of interventions) and foot-
notes to the tables were added for clarification on diverging results
reported by individual countries, when applicable.
The terminology used was based on the glossary of the
International Committee for Monitoring Assisted Reproductive
Technology (Zegers-Hochschild et al., 2017).
Results
Participation and data completeness
Table I shows the number of institutions or clinics offering ART serv-
ices with all available treatment modalities and those performing IUI
(IUI-H and IUI-D). In comparison to the 2015 data, both the total
number of reporting clinics (1343 in 2015 to 1347 in 2016) and the
overall number of reported treatments (849 811 in 2015 to 918 159
in 2016, þ8.0%) increased. Among the 51 European countries, 44 are
EIM members including 28 that are members of the European Union
(Supplementary Table SI). Non-EIM members are mainly smaller
2 Wyns et al.
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Table I Treatment frequencies afterART in European countries in 2016.
Country IVF clinics in the country Cycles/million*
IVF
clinics
Included
IVF clinics
IUI
labs
Included
IUI labs
IVF ICSI FER PGT ED IVM FOR All Women
aged 15–45
years
Population
Albania 10 1 0 83 63 0 29 0 0 175
Armenia 5 2 6 2 66 112 107 61 346
Austria 26 26 1459 5600 2662 0 9721 5886 1110
Belarus 8 7 10 7 1310 1394 270 7 16 0 0 2997
Belgium 18 18 29 29 2715 13 628 12 052 1100 1163 176 95 30 929 14 136 2738
Bosnia-Herzegovina,
Federation part
6 1 0 89 46 135
Bulgaria 35 35 1 1 920 6879 1813 379 1018 11 009 7153 1544
Cyprus 6 6 158 942 325 31 271 1727 9089 2020
Czech Republic 41 40 0 15 020 12 258 5265 32 543
Denmark 19 19 35 33 6319 5703 5059 112 484 0 19 17 696 15 917 3088
Estonia 6 6 6 6 641 1184 927 2 191 0 7 2952 11 515 2245
Finland 17 17 22 22 2756 1970 3661 73 731 0 9191 9116 1673
France 102 102 181 181 22 773 45 214 33 792 1422 1158 70 344 104 773 9066 1619
Germany 134 128 17 594 56 587 25 045 99 226
Greece 39 39 39 39 2304 15 121 4785 1251 4462 2 51 27 976 13 922 2603
Hungary 13 11 1049 3902 632 25 5608
Iceland 1 1 1 1 199 162 229 0 54 0 0 644 9248 1928
Ireland 1 215 231 260 706
Italy 200 200 360 360 7584 46 322 14 990 2844 4359 1460 77 559 7014 1280
Kazakhstan 10 5 994 1671 958 154 683 4460
Latvia 6 3 6 3 352 527 515 7 127 1528
Lithuania 6 5 6 5 295 371 92 0 0 758
Luxembourg 1 1 5 0 312 354 314 0 0 0 0 980 1684
Malta 2 2 2 0 7 273 0 0 0 0 79 359 3624 822
Moldova 4 3 5 3 0 739 181 14 934
Montenegro 5 4 5 4 7 501 58 566
North Macedonia 7 5 0 0 420 2100 288 0 122 0 4 2934
Norway 11 11 11 11 3587 3330 3363 0 0 10 280 10 101 1963
Poland 39 39 0 38 881 16 984 11 375 692 1085 33 299 31 349 816
Portugal 24 24 26 26 2462 3751 2008 127 988 1 28 9365 1726 907
Romania 19 11 19 11 1445 2034 1495 6 29 5009
Russia 199 151 34 058 43 766 31 051 4420 7122 260 558 121 235
Serbia 12 3 12 3 170 93 23 0 0 0 0 286
Slovenia 3 3 3 3 1017 2268 1389 37 7 0 7 4725 12 717 2288
Spain 247 240 366 291 5624 56 640 27 559 10 238 39 530 41 1277 140 909
Sweden 18 17 0 6235 6088 6080 304 282 18 989
Switzerland 27 27 1042 5059 4859 10 960 10 329 1309
The Nederlands 13 13 90 0 6781 7803 12 545 772 27 901 5403 1639
Ukraine 46 38 17 17 1167 9454 6967 1658 1157 8 20 411
UK 82 82 101 101 21 084 23 273 18 311 1433 3494 71 642 68 308 5240 1041
All 1467 1347 1364 1197 156 002 407 222 248 407 27 069 73 927 654 4878 918 159 7794 1410
Treatment cycles in IVF and ICSI refer to initiated cycles.
For Austria, Belgium, Iceland, Lithuania and Malta, treatment cycles IVF refer to aspirations. For Austria, Belgium, Iceland and Lithuania, treatment cycles ICSI refer to aspirations. For
Austria and Belgium, the total number of initiated cycles was only available for IVF and ICSI together, being 10 097 and 19 163, respectively.
For the Czech Republic, no distinction between IVF and ICSI is made. All cycles are counted as ICSI. For Belgium, there are 824 extra aspiration cycles for which it is not known
whether IVF or ICSI was performed.
Treatment cycles in frozen embryo replacement (FER) refer to thawings.
For Finland, Hungary, Kazakhstan, Sweden and the Netherlands, treatment cycles refer to transfers.
Treatment cycles in preimplantation genetic testing (PGT) contain both fresh and frozen cycles and refer to initiated cycles in the fresh cycles and aspirations in the frozen cycles.
Treatment cycles in egg donation (ED) refer to donation cycles and contain fresh and frozen cycles.
ED fresh: for France and Iceland, treatment cycles refer to aspirations. ED frozen: for France, Iceland, Kazakhstan, Spain, Sweden and the UK, treatment cycles refer to aspirations.
Treatment cycles in IVM refer to aspirations.
Treatment cycles in frozen oocyte replacement (FOR) refer to thawings.
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countries not offering ART services. In 2016, 40 countries delivered
data to EIM with Luxemburg providing data as a new EIM member.
Croatia, Georgia, Slovakia and Turkey failed to deliver data (9.1% of
EIM members, 11.6% in 2015). In 18 countries (45% of reporting
countries), all of the ART clinics within the country reported data sets.
Currently, 1347 clinics reported their data (91.8% of all known clinics
in Europe, 90.6% in 2015). As in 2015, the four European countries
with the largest treatment numbers in 2016 were Spain (140 909),
Russia (121 232), France (104 773) and Germany (99 226).
Size of the clinics and reporting methods
The size of reporting clinics, defined by the number of treatment
cycles, remains highly variable between and inside countries
(Supplementary Table SII). In 2016, clinics with cycle numbers between
200 and 499 were the most common (29.5% vs 29.9%). Small clinics
providing less than 100 treatments cycles per year were present in 16
countries (40% of the countries) and the proportion of clinics perform-
ing more than 1000 treatment cycles per year seems on a slight rise
over the years with 19.4% in 2016, 17.9% in 2015, 18.3% in 2014,
17.8% in 2013 and 16.9% in 2012.
Country-specific requirements and reporting methods are presented
in Supplementary Table SIII. Data collection was either voluntary (19
out of 40 countries) or compulsory. Twenty countries had only a par-
tial reporting and provided the data mainly on a voluntary basis (16/
20 countries) to medical organizations/professional societies (10 coun-
tries), based on a single person’s initiatives (five countries) or to the
national health authority (one country).
By contrast, complete reporting was achieved mainly when data col-
lection was compulsory (17/20 countries) with subsequent data com-
munication to the national health authority (all but two countries).
Transfer of data was mostly done on an aggregate basis (26 coun-
tries/40 in 2016, as in 2015).
Number of treatment cycles per technique
and availability
In 2016, 918 159 treatment cycles were reported to EIM (68 348
more than in 2015, þ8.0%). Since 1997 increasing numbers of clinics
reported to EIM, which so far recorded more than 9 772 904 treat-
ments cycles and the birth of more than 1 861 760 infants (Table II).
As shown in Table I, compared to 2015, 10 countries reported fewer
treatment cycles, but Ireland and Luxemburg were now able to pro-
vide data. Furthermore, the largest increment in reported treatment
numbers was recorded in Spain (þ21 034, þ9 clinics), France
(þ10 855, same number of clinics) and Russia (þ10 512, þ7 clinics).
The numbers of treatment cycles per technique in 2016 are presented
in Table I: ICSI was the most used (407 222, 44.4% of treatment
cycles vs 45.4% in 2015). Cycles of IVF, FER, ED, FOR, PGT and IVM
represented 17%, 27%, 8.1%, 0.5%, 2.9% and 0.0007% of all cycles,
respectively. While the distribution of the available techniques
remained similar to 2015 (IVF, FER, ED, FOR, PGT and IVM, respec-
tively 18.4%, 25.7%, 7.6%, 0.5%, 2.5% and 0.0003%), for each single
technique higher cycle numbers were registered. The steepest rise in
treatment numbers was observed in FER (þ13.9%), in ED (þ14.7%),
in FOR (þ13.6%), in PGT (þ27.4%) and IVM (þ246.8%). The propor-
tion of FER relative to fresh treatments (IVF þ ICSI) is still on the rise
(44.1% vs 40.3% in 2015 and 37.8% in 2014). The highest proportions
were reached in Armenia (75.9%), Belgium (73.7%), Czech Republic
(81.6%), Finland (77.5%), Switzerland (79.6%) and The Netherlands
(86.0%). No FER were reported/performed in Malta according to
their legislation.
Among the total of 563 224 fresh treatments (ICSI þ IVF), 72.3%
were performed with ICSI, showing a rise of þ1.2% compared to
2015. Figure 1 shows the evolution and continuing preponderance of
ICSI over conventional IVF and the increase in the proportion of FER
cycles relative to fresh cycles (IVF þ ICSI).
The number of cycles per million women of reproductive age and
per million inhabitants is shown in Table I and Supplementary Table
SIV. Availability of ART was calculated for the 20 countries with full
coverage (Supplementary Table SIV). While there is a huge variability
in availability (range 1726–15 917 per million women aged 15–45
years), ART was most available in Denmark and least available in
Portugal. Consequently, the proportion of newborns resulting from
ART born in Denmark was 5.1% of all newborns in that country.
Other countries that reported high proportions were Austria (6.2%)
and Slovenia (5.5%).
Pregnancies and deliveries after treatment
Table III shows PR and delivery rates (DR) after IVF or ICSI and after
FER (after both IVF and ICSI). Because, as in previous years, data on
......................................................................................................
Table II Number of institutions offering ART services,
treatment cycles and infants born after ART in Europe,
1997–2016.
Year Countries Clinics Cycles Cycle
increase (%)
Infants
born
1997 18 482 203 225 35 314
1998 18 521 232 225 þ14.3 21 433
1999 21 537 249 624 þ7.5 26 212
2000 22 569 275 187 þ10.2 17 887
2001 23 579 289 690 þ5.3 24 963
2002 25 631 324 238 þ11.9 24 283
2003 28 725 365 103 þ12.6 68 931
2004 29 785 367 056 þ0.5 67 973
2005 30 923 419 037 þ14.2 72 184
2006 32 998 458 759 þ9.5 87 705
2007 33 1029 493 420 þ7.7 96 690
2008 36 1051 532 260 þ7.9 107 383
2009 34 1005 537 463 þ1.0 109 239
2010 31 991 550 296 þ2.4 120 676
2011 33 1314 609 973 þ11.3 134 106
2012 34 1354 640 144 þ4.9 143 844
2013 38 1169 686 271 þ7.2 149 466
2014 39 1279 776 556 þ13.1 170 163
2015 38 1343 849 811 þ10.2 187 542
2016 40 1347 918 159 þ8.0 195 766
Total 9 772 904 1 861 760
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numbers of initiated cycles were incomplete, the outcome data were
calculated per aspiration.
Among the 40 reporting countries, 33 were able to provide both
pregnancy and delivery data per aspiration after IVF and ICSI and per
thawing for FER (completeness rate for both: 82.5%). In
Supplementary Table SIV, the numbers of deliveries for the 20 coun-
tries that had full coverage of the reporting are presented.
As in all previous reports, the PR and DR (for all types of treatment
cycles) varied significantly from one country to another. Per aspiration,
PR ranged from 13.2% to 57.1% and DR from 12.3% to 46.5% in fresh
cycles after IVF or ICSI (excluding Lithuania where DR was not avail-
able for two of the five centres reporting pregnancies). After FER per
thawing, the PR were between 21.4% and 51.9% and the DR varied
between 13% and 45.3%. Overall, PR and DR were higher for FER
cycles (per thawing) than for both fresh IVF and ICSI cycles (per aspi-
ration) (Table III).
For the third time, «freeze all» cycles were collected
(Supplementary Table SV) including cryopreservation of all oocytes
reported by 10 countries (six in 2015 and 2014) and of all embryos by
22 countries (21 in 2015 and 2014). The highest proportions of freeze
all cycles per aspiration were 3.5% at the oocyte and 17.3% at the em-
bryo level.
Cycle numbers, aspirations, transfers, pregnancies, deliveries in IVF,
ICSI and FER (after both IVF and ICSI) by country are given in the
Supplementary Tables SV–SVII.
As in 2015, ED cycle numbers were available for 26 countries al-
though 29 provided outcome data (Supplementary Table SVIII). Most
donation cycles were carried out in Spain, Russia, the Czech Republic
and Greece. Freshly collected oocytes were used in 33 406 ED cycles
and frozen oocytes (FOR) in 11 757 ED cycles. PR were only available
per embryo transfer for freshly donated oocytes (49.4%, in 2015
49.6%) and for thawed oocytes (41%, in 2015 40.3%). Outcomes for
the different countries show a high variability ranging between 9.7%
and 66.5%% for fresh oocytes and between 29.5% and 67.4% for
thawed oocytes. A total of 22 497 deliveries were reported (19 849
in 2015 and 17 259 in 2014) representing a further increase of
þ13.3%.
Age distribution
As seen in Supplementary Tables SIX and SX, age distributions of
women treated with IVF and ICSI varied between countries. Not all
countries were able to provide data on the age distribution in ICSI (six
missing) and in IVF (seven missing), some because no IVF treatments
were carried out. The highest percentage of women aged40 years and
older undergoing aspiration for IVF was found in Greece (as in 2015),
whereas the highest percentage of women aged <34 years was found
in Montenegro (as in 2015) followed by Ukraine. For ICSI, the highest
percentage of women aged 40 years and older undergoing aspiration
was found in Greece (as in 2015), whereas the highest percentage of
women undergoing aspiration aged <34 years was recorded in
Figure 1. Proportion of IVF versus ICSI and frozen embryo replacement (FER) in Europe, 1997–2016.
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Kazakhstan (in Albania in 2015 and 2014). As expected, there was an
age-dependent decline of the reported PR and DR for IVF and ICSI
treatment cycles with DR in women aged 40 years and older, ranging
between 0% and 13.1%, and 0% and 42.9% (on small numbers), re-
spectively. With regard to FER (Supplementary Table SXI), the age-
related decline was also visible and DR among women aged 40 years
and older ranged between 0% and 34.3%.
In ED cycles (Supplementary Table SXII), the age of the recipient
women did not influence outcome data and overall PR and DR were
higher than in fresh and FER cycles (in partner donation).
Numbers of embryos transferred and
multiple births
The subgroups defined by the number of embryos transferred after
IVF and ICSI together as well as multiple births are presented in
Table IV. Five countries did not report on either the number of
replaced embryos per treatment cycle or on multiplicity. While overall
most transfers involved the replacement of two embryos (51.9% of
the transfer cycles), the proportion of transfers of only one embryo
per cycle continued to rise (41.5% vs 37.7% in 2015), and the number
of transfers of three or more embryos continued to decrease (Fig. 2).
The number of countries reporting more than 50% of single embryo
transfers (elective or not) increased to 10 (same eight as in 2015 plus
Slovenia and UK). As in 2015, only Serbia reported more than 50% of
transfers with three embryos. The highest proportion of transfers of
four or more embryos was recorded in Greece (4.2% vs 4.9% in
2015). Information on the type of embryos (cleavage or blastocyst)
transferred was not available for each of the subgroups but, for the
first time, the embryo stage at the transfer was collected. Taking into
account that the embryo stage at transfer was unknown for 44.5% of
the fresh (IVFþICSI) cycles, 41.9% of the transfers were performed at
the blastocyst stage and the corresponding figure for FER was 62.2%.
As a result of decreasing numbers of embryos replaced per transfer,
the proportion of both twin and triplet deliveries continued to decline.
In 2016, twin and triplet rates for fresh IVF and ICSI cycles together
were 14.9% (range 1.1–35.7) and 0.3% (range 0–4.4), respectively.
Corresponding results for FER were 11.9% and 0.2%. In the two coun-
tries with the highest rates of single embryo replacement in fresh
cycles (84.3% for Iceland and 82.5% for Sweden), twin rates were as
low as 1.1% and 3%, respectively.
Additional information on pregnancy and delivery data are provided
in Supplementary Tables SXIII and SXIV. The reported incidence of
pregnancy loss was 16.4% after IVF þ ICSI (in 2015: 16.4%) and
18.6% after FER (in 2015: 20.6%). The proportion of lost to follow-up
was 7.8% after IVFþICSI (in 2015: 6.3%) and 7.5% after FER (in 2015:
7.4%).
Perinatal risks and complications
In 2016, data on premature deliveries were available from 18 countries
(18 countries in 2015). Premature DR based on multiplicity are pre-
sented in Supplementary Table SXV. Data from fresh IVF and ICSI,
FER and ED are pooled. The incidence of extreme preterm birth (20–
27 gestational weeks at delivery) was 1.1% in singletons (1.3% in
2015), 3.3% in twins (3.7% in 2015) and 8.4% in triplets (13.4% in
2015). Very premature birth rates (28–32 gestational weeks at
delivery) were recorded in 2.2% of singletons, 10.5% of twin pregnan-
cies (in 2015: 9.9%) and 45% in triplet pregnancies (in 2015: 39.2%).
The evolution of the proportion of premature deliveries before 37
weeks per embryo transfer according to multiplicity is shown in Fig. 3.
Term deliveries (37 weeks) were achieved in 85.9% (86.4% in 2015)
of singleton pregnancies, 44.1% (44.7% in 2015) of twin pregnancies
and 8.8% (7.5% in 2015) of triplet pregnancies.
Complications related to oocyte retrievals were reported by 33
countries (31 in 2015) and foetal reductions by 35 countries (26 in
2015) (Supplementary Table SXVI). The total number of reported
cases of ovarian hyperstimulation syndrome (OHSS) (grades 3 to 5)
was 1928, corresponding to a reported incidence of 0.21% (2167
cases in 2015; 0.25%). Other complications were less frequent (1471
cases) with a total reported incidence of 0.2% including 0.1% and
0.001% for bleeding and infection, respectively. No maternal death
was reported in 2016 (2 out of 850 000 treatment cycles in 2015). A
total of 553 foetal reductions were reported, the majority from UK,
Belgium and Spain, as in 2015.
PGT/PGT-A
Table I includes PGT and PGT-A activities, which were reported from
22 countries (23 in 2015, 22 in 2014). The main contributors were
Spain, Russia and Italy. The number of treatment cycles amounted to
27 069 representing 3.3% of initiated IVF þ ICSI and FER cycles to-
gether (21 041; 2.8% in 2015). More details on PGT/PGT-A activities
can be found in the annual reports of the ESHRE PGT consortium (De
Rycke et al., 2017)
These treatments involved 19 461 fresh cycles and 7242 thawings,
resulting in 5776 fresh and 6434 FER. In total, 2418 pregnancies
(41.9% per transfer) and 1875 deliveries (32.5% per transfer) resulted
from fresh cycles. Corresponding figures for FER were 2811 (43.7%
per transfer) and 2259 (35.1% per transfer).
IVM
A total of 654 treatments with IVM were reported from eight coun-
tries (265 from eight countries in 2015) (Table I). Most IVM cycles
were reported from Russia, as in 2015. A total of 391 transfers
resulted in 103 pregnancies (26.3% per transfer) and 43 deliveries
(11% per transfer).
FOR
A total number of 4878 thawing cycles were reported by 15 countries
(4294 from 17 countries in 2015) (Table I) with Italy and Spain being
the largest contributors (1460 and 1277 cycles, respectively). Among
3854 transfers, 1138 resulted in pregnancies (29.5%; 30.7% in 2015)
and 808 in deliveries (21%; 20.6% in 2015).
IUI
For each participating country, the institutions performing and collect-
ing data on IUI are listed in Table V. Data on IUI with husband semen
(IUI-H, Supplementary Table SXVII) or using donors’ semen (IUI-D,
Supplementary Table SXVIII) were collected by a total of 1197 institu-
tions in 28 and 23 countries (25 and 21 in 2015, respectively. Among
113 450 IUI-H (139 050 in 2015) and 46 883 IUI-D (49 001 in 2015)
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reported cycles, the numbers were the highest for IUI-H in Spain, Italy
and Belgium, and for IUI-D in Spain, Denmark and Belgium.
DR could be calculated for 109 399 IUI-H cycles (8.5% vs 7.8% in
2015) and 46 883 for IUI-D cycles (12% vs 12% in 2015).
Singleton deliveries were the most frequent regardless of the age
group with an overall rate of 91.3% for IUI-H and 92% for IUI-D
(90.6% in IUI-H, 92.1% in IUI-D in 2015). Twin and triplet rates were
8.4% and 0.3%, respectively for IUI-H, and 7.5% and 0.4% for IUI-D,
respectively (in 2015: 8.9% and 0.5%, respectively for IUI-H and 7.3%
and 0.6%, respectively for IUI-D).
Sum of fresh and FER (‘cumulative’) DR
Supplementary Table SXIX provides an estimate of a cumulative DR
(different from a true cumulative DR including outcomes of all trans-
fers performed from one aspiration). It was calculated as the ratio be-
tween the total number of deliveries from fresh embryo transfers and
FER performed during a year (numerator) and the number of aspira-
tions during the same year (denominator). The calculation included
data from 38 countries (35 countries in 2015) where an overall rate of
29.6% was recorded. The benefit taken from additional FER (over the
DR from fresh embryo transfers) was 10.5%, with the highest benefits
recorded for Ukraine (þ26.1%), Ireland (þ19.6%), Finland and Albania
(for both þ18.1%) and the lowest for North Macedonia (þ2.5%),
Belarus (þ1.6%) and Lithuania (0%).
Cross-border reproductive care
Ten countries reported data on cross-border patients: Albania,
Belarus, Denmark, Greece, Montenegro, Portugal, Serbia, Slovenia,
Spain and Switzerland. A total of 19 239 cycles (14 273 in 2015) were
reported, 22.1% (29.4% in 2015) of which involved IVF/ICSI with the
couple’s own gametes, 46.6% (47.1% in 2015) were oocyte donations
and 21.8% (22.3% in 2015) were IVF or ICSI with semen donation. In
addition, 7062 IUI with sperm donation (7714 in 2015) were regis-
tered. Information regarding the countries of origin was very incom-
plete and not reliable enough to obtain any conclusive information.
The main reasons reported by patients were to have access to a tech-
nique not legally available in their home country (39.1%; 41.7% in
2015) or to seek a higher quality treatment (23.6%; 16.6% in 2015). In
13 291 cycles (mainly from Spain), there was another, not specified,
reason to go abroad.
FP
For the first time data on FP are reported here. Eleven countries were
able to provide data on a total number of 13 689 interventions
(Supplementary Table SXX) in pre- and postpubertal patients, both
for medical and non-medical reasons. The majority of interventions
consisted of the cryopreservation of ejaculated sperm (n¼ 7877 from
11 countries) and the cryopreservation of oocytes (n¼ 4907 from
eight countries). Ovarian tissue cryopreservation was reported by two
and seven countries, respectively, for pre- and postpubertal patients
with use of postpubertal tissue through transplantation reported in
three countries (Greece, Portugal and Spain). Testicular tissue cryo-
preservation in postpubertal patients and prepubertal boys was
reported from six countries and from France only (n¼ 124),
respectively.
Discussion
This is the 20th annual report of the activity collected by EIM from
European registries on ART, IUI and for the first time also on FP.
From 1997 to 2016, the EIM of ESHRE has reported close to 10 mil-
lion treatments cycles (9 772 904) that have led to the birth of more
than 1.8 million infants.
Despite difficulties caused by the data collection system in a number
of countries, the number of participating countries has increased over
the years. The current report presents the analysis of data collected in
2016 from 40 European countries (38 in 2015) with Luxemburg pro-
viding data for the first time as a new EIM member. Non-EIM mem-
bers are mainly smaller countries not offering ART services (n¼ 5),
except for Azerbaijan and Kosovo. Amongst EIM members, Croatia,
Georgia, Slovakia and Turkey did not deliver data most likely due to
Figure 3. Proportion of premature deliveries (<37 weeks
of gestation in relation to pregnancies 37 week of gesta-
tion) in singleton, in twin and in triplet pregnancies in
Europe, 2006–2016.
Figure 2. Number of embryos transferred in IVF and ICSI
during fresh cycles in Europe, 1997–2016.
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Table V IUI with husband (IUI-H) or donor (IUI-D) semen in 2016.
Country IUI-H IUI-D
Cycles Deliveries Deliveries
(%)
Singleton
(%)
Twin
(%)
Triplet
(%)
Cycles Deliveries Deliveries
(%)
Singleton
(%)
Twin
(%)
Triplet
(%)
Albania
Armemia 275 68 24.7 79.6 20.4 0.0 48 11 22.9 88.9 11.1 0.0
Austria
Belarus 1017 102 10.0 91.1 8.9 0.0 18 8 44.4 100.0 0.0 0.0
Belgium 12 296 904 7.4 95.2 4.6 0.1 8444 896 10.6 96.3 3.7 0.0
Bosnia-Herzegovina,
Federation part
77 4 5.2 100.0 0.0 0.0
Bulgaria 2515 219 8.7 90.0 10.0 0.0 554 59 10.6 94.9 5.1 0.0
Cyprus
Czech Republic
Denmark 9977 1118 11.2 90.0 9.8 0.2 9390 569 6.1 94.4 5.5 0.2
Estonia 90 2 2.2 100.0 0.0 0.0 122 11 9.0 100.0 0.0 0.0
Finland 2936 249 8.5 1125 134 11.9
France 49 498 5254 10.6 90.4 9.4 0.2 2870 544 19.0 89.9 9.7 0.4
Georgia
Germany
Greece 3266 210 6.4 93.7 6.3 0.0 309 42 13.6 91.9 5.4 2.7
Hungary
Iceland 69 6 8.7 100.0 0.0 0.0 167 21 12.6 100.0 0.0 0.0
Ireland 81 8 9.9 100.0 0.0 0.0
Italy 21 053 1531 7.3 91.2 8.2 0.6 714 98 13.7 83.7 11.2 5.1
Kazakhstan 2622 23 0.9 100.0 0.0 0.0
Latvia 103 13 12.6 100.0 0.0 0.0 64 5 7.8 100.0 0.0 0.0
Lithuania 246 15 6.1 100.0 0.0 0.0
Luxembourg 264 34 12.9 94.1 5.9 0.0 84 10 11.9 100.0 0.0 0.0
Malta
Moldova 81 9 11.1 100.0 0.0 0.0
Montenegro 193 19 9.8 89.5 10.5 0.0
Norway 325 47 14.5 83.0 17.0 0.0 614 119 19.4 95.8 4.2 0.0
North Macedonia 1108 23 2.1 95.7 4.3 0.0 79 4 5.1 100.0 0.0 0.0
Poland 11 149 751 6.7 94.5 5.1 0.4 2053 225 11.0 91.7 7.9 0.5
Portugal 2095 190 9.1 85.7 13.8 0.5 185 42 22.7 92.9 7.1 0.0
Romania 2542 143 5.6 66.2 33.8 0.0 278 27 9.7 77.8 22.2 0.0
Russia 9106 1002 11.0 93.1 6.6 0.3 3897 545 14.0 93.4 6.3 0.4
Serbia 393 32 8.1 96.9 3.1 0.0
Slovenia 551 43 7.8 88.4 11.6 0.0
Spain 24 130 2404 10.0 90.5 9.2 0.3 12 333 1914 15.5 88.3 11.2 0.5
Sweden 1168 196 16.8 96.9 3.1 0.0
Switzerland
The Nederlands
Ukraine 1032 91 8.8 95.6 4.4 0.0 360 43 11.9 97.7 2.3 0.0
UK 4051 5398 707 13.1 92.6 6.8 0.6
All* 162 948 14 495 8.9 91.0 8.8 0.3 50 467 6249 12.4 91.9 7.7 0.4
*Total refers to these countries where data were reported, and mean percentage was computed on countries with complete information.
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organizational problems or local regulatory problems (Calhaz-Jorge
et al., 2020).
Excluding the five small European countries in which ART is not
available, the rate of participation at the country level is as high as 87%
of European countries (90.9% of EIM members) while at the level of
IVF clinics, the proportion of those reporting data sets is 91.8% (vs
90.6% in 2015; De Geyter et al., 2020). Although the participation of
some of the countries fluctuated over time, reported ART treatment
numbers are on a continuous rise (þ8% as compared to 2015) as are
the infants born from ART (þ4.4% compared to 2015).
Moreover, although the level of completeness is highly variable
among countries, 20 countries were able to present data from all IVF
clinics (in 2015: 18 and in 2014: 14 countries). Efforts to achieve in-
creased participation and higher completeness of the data aim at an
improved transparency and vigilance in reproductive care. However,
because of the variety in collection systems, absence or limited pres-
ence of data validation methods, differences in definitions of collected
items and country-specific practices (e.g. freeze all cycles, embryo
transfer policy) that may, among other reasons, be influenced by eco-
nomic issues, interpretation of the data should remain cautious.
Progress towards harmonization of data collections could prove helpful
in the future to achieve a higher quality of outcome data for professio-
nals but also for other stakeholders involved in societal, political and
economic decisions in medically assisted reproduction (MAR), as well
as tissue and cell banking for FP.
Access to care is one of the important and very relevant pieces of
information generated by the EIM. Considering that it was estimated
that 1500 ART cycles per million inhabitants per year should cover the
needs in infertility care (The ESHRE Capri Workshop group, 2008),
we noticed that 60% of the countries in which complete data sets
were available (12 out of 20) reached this level of access in 2016 (vs
55.6% in 2012, 64.3% in 2014 and 61.1% in 2015). Using the number
of women of reproductive age as the denominator and eliminating
thereby the impact of age differences among countries, access to care
(based on all types of cycles) appeared highly variable, ranging from
1726 to 15 917 cycles per women aged 15–45 years. As the popula-
tion needs in ART were estimated at a time when FER was not cur-
rent practice (2001), any interpretation of treatment availability should
be cautious. Indeed, FER cycles were included in the calculation on
availability and represent a quite high proportion of ART cycles nowa-
days (in 2016, 44.1% of ART cycles when fresh IVFþICSI cycles are
used as the denominator). Moreover, considering that cross-border
care may have an impact on accessibility in some countries, data inter-
pretation will remain difficult before full traceability of all MAR proce-
dures becomes available.
Considering the different treatment modalities, ICSI remains the
most used and seems to have stabilized in recent years (Table I;
Fig. 1), whereas FER is the second most used technique with a pro-
gressive increase over the years in the proportion of FER relative to
fresh IVF and ICSI cycles (37.8% in 2014, 40.3% in 2015 and 44% in
2016). Changes in ART practices with higher numbers of freeze all
cycles, a reduced number of embryos replaced per transfer and higher
survival rates of cryopreserved embryos with the implementation of
vitrification (Rienzi et al., 2017) may all explain this evolution. While
freeze all cycles have been registered since 2014, showing a 42% in-
crease in reported cycles in 2016 compared to 2015 (Supplementary
Table SV), the distinction between techniques of cryopreservation
could not be registered by EIM. Enhanced reporting of IVM, PGT, ED
and FOR in 2016 may be a reflection of the increased use of these
treatment modalities. Expanding the data collection in large registries
such as EIM for techniques like IVM and PGT-A, or to other new tech-
niques or laboratory adjuncts (Harper et al., 2017), could help to un-
derscore analysis of their efficacy and safety in the future.
Owing to segmentation of treatments (i.e. treatment is not always a
continuous sequence of single procedures but may, for example, in-
clude several oocyte retrievals for one transfer or several transfers for
frozen cycles), such as for freeze all cycles, and the implementation of
new technologies in ART, the cumulative DR per cycle or per aspira-
tion will become the most important outcome indicator of treatment
effectiveness. To date, the EIM has gathered data on an aggregate ba-
sis precluding thereby the calculation of true cumulative livebirths
rates. Hence, as a surrogate indicator or proxy of true cumulative
rates, fresh and FER during the same calendar year have been consid-
ered. Based on data from 38 countries, cumulative DR reached 29.6%
during a 1-year period with a multiple DR of 13.8% and a rate of single
embryo transfers of 41.5% in 2016. The absence of a link between
cryopreserved embryos and their original cycle, and the limited obser-
vation period of 1 year where an unknown number of ART cycles was
performed, do not allow comparisons with other registries. However,
after seven consecutive ART cycles (fresh and frozen-thawed embryo
transfer cycles counted consecutively) the 2011 data registered by the
National Perinatal Epidemiology and Statistics Unit for Australia–New
Zealand, including 73.2% single embryo transfers, showed a cumulative
livebirth rate of 41.1% and a multiple DR of only 6.9% (National
Perinatal Epidemiology and Statistics Unit, https://npesu.unsw.edu.au).
Besides local regulations and economic issues that may restrict
treatment strategies, the improved awareness of ART outcomes by
patients and physicians should guide future decisions. In this regard,
the reduction in the number of embryos replaced in a cycle is a main
trend that has been recorded by the EIM registry over the years
(Fig. 2). While the transfer of two embryos remains the most fre-
quently performed approach (51.9% of the transfers), single embryo
transfers (whether elective or not) represented 41.5% of the transfers
in 2016 and were carried out in the majority of treatment cycles for
10 of the countries. Transfers of four or more embryos were per-
formed in very few countries and represent only 0.4% of all transfers.
The evolution of the transfer policies in clinics often parallels the im-
plementation of embryo culture to the blastocyst stage. However, the
quality of evidence to support blastocyst transfers is still low
(Glujovsky et al., 2016). For the first time in 2016, EIM data collection
allowed separate analysis of blastocyst and cleavage stage embryo
transfers, showing that the majority of embryos were transferred at
the blastocyst stage (41.9% for fresh IVF þ ICSI and 62.2% for FER).
Although figures are not available for DR yet, PR per transfer were
the highest for blastocysts (39.7% vs 28.3% for cleavage stage em-
bryos). Keeping in mind that the objective of an IVF/ICSI treatment is
the delivery of a single healthy child, with a twin pregnancy being
regarded as a complication (Land and Evers, 2003), further progress
towards a reduction of prematurity associated with multiple births
should be obtained at the expense of a reduced proportion of double
embryo transfers. Indeed, whereas triplet rates remain low after a sig-
nificant drop over the years (Ferraretti et al., 2017), twin rates did not
follow the same decreasing slope and the resulting prematurity (37
weeks) was still observed in more than half of the deliveries.
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Compared to singleton deliveries the risk of extreme prematurity was in-
creased by 3-fold and of very preterm birth by nearly 5-fold for twin de-
liveries. Rates of twins and triplets were slightly lower after FER than
after fresh IVF þ ICSI treatments, which could also contribute to the de-
creasing multiple deliveries recorded in the recent years. Furthermore,
the practice of foetal reduction for the prevention of multiple births was
reported by 35 countries. However, it is not known which of these
approaches is having the real impact on the reduction of multiples.
Regarding other safety aspects, no maternal death after ART was
reported in 2016 (Supplementary Table SXVI) and the proportions of
OHSS, infections and haemorrhage were low and quite stable over
time although it is assumed that the complications of ART remain gen-
erally underreported.
The future of MAR registries should focus on the health of
infants as an increasing number of children are born after ART,
with incidences as high as 5.1% of all newborns in Denmark and
7.7% in Spain in 2016. Moreover, considering the increasing use of
ED, FOR and the extension of using FP measures for medical rea-
sons to non-medical indications, including planned postponement
of motherhood, we may expect ART to contribute more and more
to demography. Hence, transparency and vigilance in ART will
more than ever be essential to all stakeholders with, as a main re-
quirement, the need to level up the quality of collected data.
Prospective compulsory registration systems, including an interna-
tional coding system to follow gametes and embryos across country
borders, should therefore become available to countries rather
than the current retrospective aggregate data registration (De
Geyter et al., 2016; Kissin et al., 2019).
Supplementary data
Supplementary data are available at Human Reproduction Open online.
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Appendix
Contact persons who are collaborators and represent the data collec-
tion programmes in participating European countries, 2016.
Albania
Prof. Orion Gliozheni, University Hospital for Obstetrics &
Gynecology, Department of Obstetrics & Gynecology, Bul. B. Curri,
Tirana, Albania. Tel: þ355 4222 36 32; Fax: þ355 42 257 688;
Mobile: þ355 68 20 29 313; E-mail: glorion@abcom.al
Armenia
Mr Eduard Hambartsoumian, Fertility Center, IVF Unit, 4 Tigvan Nets,
375 010 Yerevan, Armenia. Tel: þ374 10 544 368; E-mail: hambart-
soumian@hotmail.com
Austria
Prof. Dr Heinz Strohmer, Dr Obruca & Dr Strohmer Partnerschaft
Goldenes Kreuz-Kinderwunschzentrum, Lazarettgasse 16-18, 1090
Wien, Austria. Tel: þ43 401 111 400; Fax: þ43 401 111 401; E-mail:
heinz.strohmer@kinderwunschzentrum.at
Belarus
Dr Elena Petrovskaya (Alena Piatrouskaya), ART centre ‘Embryo’,
Filimonova 53, 220053 Minsk, Belarus. Tel: þ375 293 830 570; Email:
elenaembryoby@gmail.com
Dr Oleg Tishkevich, Centre For Assisted Reproduction ‘Embryo’
Belivpul, Filimonova Str. 53, 220 114 Minsk, Belarus. Tel: þ375 296
222 722; Fax: þ375 172 376 404; Mobile: þ375 296 222 722; E-mail:
tishol@tut.by
Belgium
Dr Kris Bogaerts, I-Biostat, Kapucijnenvoer 35 bus 7001, 3000 Leuven,
Belgium. Tel: þ32 (0) 16 33 68 90; Fax: þ32 (0) 16 33 70 15; E-mail:
kris.bogaerts@med.kuleuven.be
Prof. Christine Wyns, Gynaecology-Andrology, Cliniques
Universitaires Saint Luc, Service FIV- Andrology, Universite´ Catholique
de Louvain; Av. Hippocrate, 10, 1200 Brussels, Belgium. Tel: þ32
27646576; Fax: þ32 27649050; Mobile: þ32 477943374; E-mail:
christine.wyns@uclouvain.be
Bosnia
Professor Dr Devleta Balic, Zavod za humanu reprodukciju ‘Dr Balic’,
Kojsino 25, 75000 Tuzla, Bosnia, Herzegovina. Tel: þ387 35 260 650;
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